Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.23.3
Commitments and Contingencies (Details)
₪ in Thousands, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 23, 2023
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2023
ILS (₪)
Mar. 31, 2022
USD ($)
Mar. 31, 2022
ILS (₪)
Aug. 31, 2021
USD ($)
Aug. 31, 2021
ILS (₪)
Mar. 31, 2021
USD ($)
Mar. 31, 2021
ILS (₪)
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2023
ILS (₪)
Commitments and Contingencies (Details) [Line Items]                        
Aggregate budget   $ 3,164 ₪ 11,283 $ 4,094 ₪ 13,004 $ 1,778 ₪ 5,737 $ 3,286 ₪ 10,879      
Aggregate revised budget               $ 2,118 ₪ 6,753      
Percentage of approved budgets   30.00% 30.00% 30.00% 30.00% 50.00% 50.00% 30.00% 30.00%      
Received amount of programs | ₪                       ₪ 5,289
Received amount                     $ 395 1,365
Total approved grants                     9,353 32,068
Total grants received                     7,563 ₪ 25,825
Total grants subject to royalties                     6,973  
Total contingent obligation                     $ 7,424  
Received fees $ 1,411                      
Collaboration agreement, description                     The fees will be paid in installments of $500 within 30 days of the Effective Date and three additional installments of $500, $200 and $211 upon completion of certain activities under the research plan. Unless terminated earlier, this agreement will remain in effect until (a) a period of eighteen (18) months after the Effective Date or (b) completion of the project plan and submission and approval of the final report, whichever occurs sooner, unless otherwise extended. The consideration is recorded as a reduction of R&D expenses, net in the condensed consolidated statements of operations according to the input model method on a cost-to-cost basis. The remainder of the consideration is recorded as other accounts payable in the condensed consolidated balance sheets. The fees will be paid in installments of $500 within 30 days of the Effective Date and three additional installments of $500, $200 and $211 upon completion of certain activities under the research plan. Unless terminated earlier, this agreement will remain in effect until (a) a period of eighteen (18) months after the Effective Date or (b) completion of the project plan and submission and approval of the final report, whichever occurs sooner, unless otherwise extended. The consideration is recorded as a reduction of R&D expenses, net in the condensed consolidated statements of operations according to the input model method on a cost-to-cost basis. The remainder of the consideration is recorded as other accounts payable in the condensed consolidated balance sheets.
Statements of operations                   $ 56 $ 312  
Total fund                     $ 1,200  
Minimum [Member]                        
Commitments and Contingencies (Details) [Line Items]                        
Royalties rate                     3.00% 3.00%
Maximum [Member]                        
Commitments and Contingencies (Details) [Line Items]                        
Royalties rate                     3.50% 3.50%
IIA [Member]                        
Commitments and Contingencies (Details) [Line Items]                        
Received amount of programs                     $ 577 ₪ 1,912
Received amount                     328 ₪ 1,185
IIA [Member]                        
Commitments and Contingencies (Details) [Line Items]                        
Received amount of programs                     $ 1,622